230 related articles for article (PubMed ID: 15994369)
1. Development of simplified vasoactive intestinal peptide analogs with receptor selectivity and stability for human vasoactive intestinal peptide/pituitary adenylate cyclase-activating polypeptide receptors.
Igarashi H; Ito T; Mantey SA; Pradhan TK; Hou W; Coy DH; Jensen RT
J Pharmacol Exp Ther; 2005 Oct; 315(1):370-81. PubMed ID: 15994369
[TBL] [Abstract][Full Text] [Related]
2. Elucidation of the vasoactive intestinal peptide pharmacophore for VPAC(2) receptors in human and rat and comparison to the pharmacophore for VPAC(1) receptors.
Igarashi H; Ito T; Pradhan TK; Mantey SA; Hou W; Coy DH; Jensen RT
J Pharmacol Exp Ther; 2002 Nov; 303(2):445-60. PubMed ID: 12388623
[TBL] [Abstract][Full Text] [Related]
3. Evidence for a direct interaction between the Thr11 residue of vasoactive intestinal polypeptide and Tyr184 located in the first extracellular loop of the VPAC2 receptor.
Nachtergael I; Vertongen P; Langer I; Perret J; Robberecht P; Waelbroeck M
Biochem J; 2003 Mar; 370(Pt 3):1003-9. PubMed ID: 12475394
[TBL] [Abstract][Full Text] [Related]
4. Immunocytochemical identification of VPAC1, VPAC2, and PAC1 receptors in normal and neoplastic human tissues with subtype-specific antibodies.
Schulz S; Röcken C; Mawrin C; Weise W; Höllt V; Schulz S
Clin Cancer Res; 2004 Dec; 10(24):8235-42. PubMed ID: 15623599
[TBL] [Abstract][Full Text] [Related]
5. VPAC2 receptors mediate vasoactive intestinal peptide-induced neuroprotection against neonatal excitotoxic brain lesions in mice.
Rangon CM; Goursaud S; Medja F; Lelièvre V; Mounien L; Husson I; Brabet P; Jégou S; Janet T; Gressens P
J Pharmacol Exp Ther; 2005 Aug; 314(2):745-52. PubMed ID: 15872042
[TBL] [Abstract][Full Text] [Related]
6. Characterization of novel splice variants of the PAC1 receptor in human neuroblastoma cells: consequences for signaling by VIP and PACAP.
Lutz EM; Ronaldson E; Shaw P; Johnson MS; Holland PJ; Mitchell R
Mol Cell Neurosci; 2006 Feb; 31(2):193-209. PubMed ID: 16226889
[TBL] [Abstract][Full Text] [Related]
7. Expression localisation and functional activity of pituitary adenylate cyclase-activating polypeptide, vasoactive intestinal polypeptide and their receptors in mouse ovary.
Barberi M; Muciaccia B; Morelli MB; Stefanini M; Cecconi S; Canipari R
Reproduction; 2007 Aug; 134(2):281-92. PubMed ID: 17660238
[TBL] [Abstract][Full Text] [Related]
8. Receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide in turkey cerebral cortex: characterization by [125I]-VIP binding and effects on cyclic AMP synthesis.
Zawilska JB; Niewiadomski P; Nowak JZ
Gen Comp Endocrinol; 2004 Jun; 137(2):187-95. PubMed ID: 15158130
[TBL] [Abstract][Full Text] [Related]
9. Pituitary adenylate cyclase-activating peptide/vasoactive intestinal peptide receptors in human normal mammary gland and breast cancer tissue.
García-Fernández MO; Collado B; Bodega G; Cortés J; Ruíz-Villaespesa A; Carmena MJ; Prieto JC
Gynecol Endocrinol; 2005 Jun; 20(6):327-33. PubMed ID: 16019382
[TBL] [Abstract][Full Text] [Related]
10. Characterization and expression of different pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide receptors in rat ovarian follicles.
Vaccari S; Latini S; Barberi M; Teti A; Stefanini M; Canipari R
J Endocrinol; 2006 Oct; 191(1):287-99. PubMed ID: 17065411
[TBL] [Abstract][Full Text] [Related]
11. Receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide in the goose cerebral cortex.
Zawilska JB; Niewiadomski P; Nowak JZ
Pol J Pharmacol; 2004; 56(2):203-11. PubMed ID: 15156071
[TBL] [Abstract][Full Text] [Related]
12. Vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide stimulate interleukin-6 production in prostate cancer cells and prostatic epithelial cells.
Nagakawa O; Junicho A; Akashi T; Koizumi K; Matsuda T; Fuse H; Saiki I
Oncol Rep; 2005 Jun; 13(6):1217-21. PubMed ID: 15870945
[TBL] [Abstract][Full Text] [Related]
13. Elucidation of vasoactive intestinal peptide pharmacophore for VPAC(1) receptors in human, rat, and guinea pig.
Igarashi H; Ito T; Hou W; Mantey SA; Pradhan TK; Ulrich CD; Hocart SJ; Coy DH; Jensen RT
J Pharmacol Exp Ther; 2002 Apr; 301(1):37-50. PubMed ID: 11907155
[TBL] [Abstract][Full Text] [Related]
14. Long-acting analogue of vasoactive intestinal peptide, [R15, 20, 21, L17]-VIP-GRR (IK312532), protects rat alveolar L2 cells from the cytotoxicity of cigarette smoke.
Onoue S; Endo K; Ohmori Y; Yamada S; Kimura R; Yajima T; Kashimoto K
Regul Pept; 2004 Dec; 123(1-3):193-9. PubMed ID: 15518912
[TBL] [Abstract][Full Text] [Related]
15. Distribution of vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide receptors (VPAC1, VPAC2, and PAC1 receptor) in the rat brain.
Joo KM; Chung YH; Kim MK; Nam RH; Lee BL; Lee KH; Cha CI
J Comp Neurol; 2004 Aug; 476(4):388-413. PubMed ID: 15282712
[TBL] [Abstract][Full Text] [Related]
16. Effect of positive charge in VIP 16gamma-glutamyl diamino derivatives on hVPAC1 and hVPAC2 receptor function.
de Maria S; Metafora V; Metafora S; Ravagnan G; Cartení M; Pontoni G; Facchiano A; Lepretti M; Severino B; Caliendo G; Santagada V; Langer I; Robberecht P
J Pept Sci; 2008 Jan; 14(1):102-9. PubMed ID: 17883247
[TBL] [Abstract][Full Text] [Related]
17. Pituitary adenylate cyclase-activating polypeptide, vasoactive intestinal polypeptide and their receptors: distribution and involvement in the secretion of Podarcis sicula adrenal gland.
Valiante S; Prisco M; Sciarrillo R; De Falco M; Capaldo A; Gay F; Andreuccetti P; Laforgia V; Varano L
J Endocrinol; 2008 Feb; 196(2):291-303. PubMed ID: 18252952
[TBL] [Abstract][Full Text] [Related]
18. Effect of inactivating mutations on phosphorylation and internalization of the human VPAC2 receptor.
Langer I; Langlet C; Robberecht P
J Mol Endocrinol; 2005 Apr; 34(2):405-14. PubMed ID: 15821106
[TBL] [Abstract][Full Text] [Related]
19. Identification of key residues for interaction of vasoactive intestinal peptide with human VPAC1 and VPAC2 receptors and development of a highly selective VPAC1 receptor agonist. Alanine scanning and molecular modeling of the peptide.
Nicole P; Lins L; Rouyer-Fessard C; Drouot C; Fulcrand P; Thomas A; Couvineau A; Martinez J; Brasseur R; Laburthe M
J Biol Chem; 2000 Aug; 275(31):24003-12. PubMed ID: 10801840
[TBL] [Abstract][Full Text] [Related]
20. Human H9 cells proliferation is differently controlled by vasoactive intestinal peptide or peptide histidine methionine: implication of a GTP-insensitive form of VPAC1 receptor.
Goursaud S; Pineau N; Becq-Giraudon L; Gressens P; Muller JM; Janet T
J Neuroimmunol; 2005 Jan; 158(1-2):94-105. PubMed ID: 15589042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]